Full Archive
Radiofrequency Ablation for Recurrent Pleural Mesothelioma
Cancers 2026 January 26 [Link] Hiroshi Kodama, Kozo Kuribayashi, Haruyuki Takaki, Kosuke Matsuda, Takashi Shinkai, Reona Wada, Atsushi Ogasawara, Masaki Hashimoto, Daichi Fujimoto, Toshiyuki Minami, Soichiro Funaki, Takashi Kijima, Koichiro Yamakado Abstract Background/Objectives: Pleural mesothelioma (PM) frequently recurs despite multimodal therapy. Here, we aimed to retrospectively evaluate the safety and potential clinical benefit of radiofrequency…
Read MoreThe Role of Dosimetric Parameters in Radiation Pneumonitis: A Functional Approach in Adjuvant Treatment of Malignant Pleural Mesothelioma
Cancers 2026 January 27 [Link] Luca Dominici, Davide Franceschini, Mauro Loi, Ruggero Spoto, Antonio Marco Marzo, Beatrice Marini, Mariya Boyanova Ilieva, Nicola Lambri, Francesco La Fauci, Ciro Franzese, Marta Scorsetti Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive neoplasm, the major cause of which is asbestos exposure. Adjuvant radiotherapy after pleurectomy/decortication (P/D) aims at…
Read MoreBAP-1 in the diagnosis of malignant pleural mesothelioma
Respiratory Medicine and Research 2025 November 28 [Link] Irene Sansano, Ana Vázquez, Oscar Persiva, Marc Simó, Leire Sánchez, Pilar Montoya, Carme Dinarès, Carmen Alemán Abstract Background: The diagnosis of malignant pleural mesothelioma (MPM) can be challenging for clinicians and pathologists. Patients and methods: This study included all patients diagnosed with pleural mesothelioma between October 2013…
Read MoreValidation of chemoresistance phenotypes in pleural mesothelioma across 2D, 3D, and in vivo models
Scientific Reports 2026 February 11 [Link] Huaikai Shi, Sakthi Priya Selvamani, Richard Zelei, Ling Zhuang, Dongwei Wang, Ben Johnson, Vivek Dharwal, Duo Xu, Yiwei Wang, Tristan Rutland, Sonja Klebe, Steven Kao, Anthony Linton, Elham Hosseini-Beheshti, Yuen Yee Cheng Abstract Pleural mesothelioma (PM) is a highly aggressive cancer with limited treatment efficacy and poor prognosis. Conventional…
Read MoreFeasibility of multimodality treatment, including pleurectomy decortication, in carefully selected patients with sarcomatoid mesothelioma
Translational Lung Cancer Research 202t6 January 31 [Link] Moshe Lapidot, Emanuele Mazzola, Raphael Bueno Abstract Background: Pleural mesothelioma (PM) represents an uncommon and exceptionally lethal malignancy. The sarcomatoid subtype constitutes the rarest histological variant, traditionally linked to the worst prognosis, while the advantages of operative intervention remain inadequately established. In this study, we present findings…
Read MoreConstruction and validation of a prognostic risk score model for malignant mesothelioma
Discover Oncology 2026 February 8 [Link] Qingzheng An, Fengyun Cui, Guangming Shi, Longkun Ni, Kun Xiao, Feng Tian, Yuezhi Chen, Leping Li, Changqing Jing, Guodong Lian Abstract Purpose: Malignant mesothelioma is a rare, aggressive cancer. Although the World Health Organization (WHO) histologic subtypes–epithelioid (best prognosis), biphasic, and sarcomatoid (worst prognosis)—provide baseline stratification, architectural and molecular…
Read MoreThe specificity of HEG1 as mesothelioma marker depends on the differential diagnosis
Virchows Archiv 2026 March [Link] Ben Davidson, Lara Maria Stričak, Arild Holth, Annette Torgunrud, Jeremias Wohlschlaeger, Martin Tötsch , Assia Bassarova Abstract The objective of this study was to analyze the diagnostic role of HEG homolog 1 (HEG1) in cancers affecting the serosal cavities. HEG1 protein expression by immunohistochemistry was analyzed in 534 specimens (341…
Read MoreDisaster on MARS2? Lessons Learned from Modern Day Outcomes of Surgery for Pleural Mesothelioma
The Annals of Thoracic Surgery 2026 February 2 [Link] Shubham Gulati, Andrea Wolf, Jai Mehrotra-Varma, Stephanie Tuminello, Emanuela Taioli, Raja Flores Abstract Background: The Mesothelioma and Radical Surgery 2 (MARS2) trial has drawn into question pleurectomy/decortication (PD) for the treatment of pleural mesothelioma. This trial’s evaluation of resectability (poor positron emission tomography/computed tomography utilization, patients…
Read MoreNeoadjuvant Pressurized Intraperitoneal Aerosol Chemotherapy for Conversion to Cytoreductive Surgery in Unresectable Malignant Peritoneal Mesothelioma: A Report of 2 Cases
The American Journal of Case Reports 2026 February [Link] Arnaldo Urbano-Ruiz, Bruna Latronico Palma, Ronaldo Elias Carnut Rego, Daniel Bianqui Guaraldo da Silva, Bianca Fava, Erlan Araujo Falcão , Michelle Louise Rodrigues Barbosa da Silva, Julia Rodrigues Leandro Uliano Abstract BACKGROUND Peritoneal mesothelioma (PM) is the second most common presentation site of malignant mesothelioma. The…
Read MoreAdverse Renal Outcomes in Patients With Mesothelioma-A Territory-Wide Real-World Data
Cancer Medicine 2026 February [Link] Wang Chun Kwok, James Chung Man Ho, Isaac Sze Him Leung, Desmond Yat Hin Yap Abstract Introduction: Advances in mesothelioma management have translated into longer patient survival and different treatment-related side effects including nephrotoxicity. The risk of developing adverse renal outcomes in patients with mesothelioma and associated risk factors remains…
Read More
Skip to content